Martha Morrell is CHIEF MEDICAL OFFICER at NeuroPace Inc (NPCE). They have made 5 open-market trades across 1 company since 2023, most recently 2026-09-24.
CIK 0001855616
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NPCE | 51,357 | $629K |
Shares reported on the most recent Form 4, priced at the 2026-09-25 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NPCE | SELL · 10b5-1 | 2025-12-15 | 2026-03-04 | $15.97 | $399K | +5.3% | +8.5% | +21.1% |
| NPCE | SELL | 2025-02-21 | 2025-02-25 | $13.72 | $2.1M | -19.2% | -9.0% | -7.0% |
| NPCE | SELL · 10b5-1 | 2025-01-29 | 2025-01-31 | $15.00 | $5K | -11.4% | -13.4% | -13.6% |
| NPCE | SELL · 10b5-1 | 2025-01-24 | 2025-01-28 | $15.01 | $48K | -9.0% | -12.9% | -19.4% |
| NPCE | SELL | 2024-02-02 | 2024-02-06 | $15.09 | $531K | +3.5% | -11.2% | -15.3% |
| NPCE | SELL | 2024-01-30 | 2024-02-01 | $15.10 | $379K | -1.4% | -10.8% | -10.2% |
| NPCE | SELL · 10b5-1 | 2024-01-24 | 2024-01-26 | $15.03 | $12K | +16.0% | +18.4% | -9.3% |
| NPCE | SELL | 2023-12-26 | 2023-12-28 | $10.12 | $136K | +25.1% | +48.8% | +37.5% |
| NPCE | SELL · 10b5-1 | 2023-12-20 | 2023-12-22 | $10.14 | $28K | +19.8% | +62.5% | +48.5% |
| NPCE | SELL | 2023-12-06 | 2023-12-07 | $8.16 | $180K | +17.7% | +46.8% | +66.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.